Immune responses of two recombinant adenoviruses expressing VP1 antigens of FMDV fused with porcine granulocyte macrophage colony-stimulating factor
Vaccine, ISSN: 0264-410X, Vol: 25, Issue: 49, Page: 8209-8219
2007
- 24Citations
- 32Captures
Metric Options: Counts1 Year3 YearSelecting the 1-year or 3-year option will change the metrics count to percentiles, illustrating how an article or review compares to other articles or reviews within the selected time period in the same journal. Selecting the 1-year option compares the metrics against other articles/reviews that were also published in the same calendar year. Selecting the 3-year option compares the metrics against other articles/reviews that were also published in the same calendar year plus the two years prior.
Example: if you select the 1-year option for an article published in 2019 and a metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019. If you select the 3-year option for the same article published in 2019 and the metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019, 2018 and 2017.
Citation Benchmarking is provided by Scopus and SciVal and is different from the metrics context provided by PlumX Metrics.
Example: if you select the 1-year option for an article published in 2019 and a metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019. If you select the 3-year option for the same article published in 2019 and the metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019, 2018 and 2017.
Citation Benchmarking is provided by Scopus and SciVal and is different from the metrics context provided by PlumX Metrics.
Metrics Details
- Citations24
- Citation Indexes24
- 24
- CrossRef18
- Captures32
- Readers32
- 32
Article Description
Foot-and-mouth disease (FMD) is a highly contagious and economically devastating vesicular disease of cloven-hoofed animals. In the present report, we constructed and characterized the immune responses conferred by two recombinant adenoviruses expressing VP1 epitopes (three amino acid residues 21–60, 141–160 and 200–213 in VP1, designated VPe) or VP1 protein of FMDV fused with porcine granulocyte macrophage colony-stimulating factor (named rAd-GMCSF-VPe and rAd-GMCSF-VP1). Seven groups of female BALB/c mice each containing 18 mice were inoculated subcutaneously twice at 2-week intervals with the recombinant adenoviruses. Then the protective efficacy of the two adenoviruses was detected in guinea pigs and swine. The results showed that the highest levels of FMDV-specific T cell proliferation, IFN-γ and IL-4 could be induced by rAd-GMCSF-VPe expressing fusion GMCSF-VPe, and the highest level of FMDV-specific humoral immune responses could be induced by rAd-GMCSF-VP1 expressing fusion GMCSF-VP1 in mice. All guinea pigs and swine co-administrated with rAd-GMCSF-VPe and rAd-GMCSF-VP1 were protected from viral challenge, even though the neutralizing antibody titers were significantly lower than those in the group inoculated with inactivated FMD vaccine. It demonstrated that co-administration of rAd-GMCSF-VPe and rAd-GMCSF-VP1 might be attractive candidate vaccines for preventing FMDV infection.
Bibliographic Details
http://www.sciencedirect.com/science/article/pii/S0264410X07011073; http://dx.doi.org/10.1016/j.vaccine.2007.09.062; http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&scp=36048936939&origin=inward; http://www.ncbi.nlm.nih.gov/pubmed/17980939; https://linkinghub.elsevier.com/retrieve/pii/S0264410X07011073; https://dx.doi.org/10.1016/j.vaccine.2007.09.062
Elsevier BV
Provide Feedback
Have ideas for a new metric? Would you like to see something else here?Let us know